Abstract | PURPOSE: PATIENTS AND METHOD: RESULTS: IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 h. IOP decreased substantially in eight eyes; in four eyes, adjuvant cyclocryoapplication was necessary. The last eye was affected by a retinal detachment 1 month after IVB. No side effects were observed. DISCUSSION: CONCLUSION:
|
Authors | O Ouhadj, I Chergui, L Mendil, M T Nouri |
Journal | Journal francais d'ophtalmologie
(J Fr Ophtalmol)
Vol. 32
Issue 2
Pg. 112-6
(Feb 2009)
ISSN: 1773-0597 [Electronic] France |
Vernacular Title | Injection intravitréenne de Bevacizumab (Avastin) dans le traitement du glaucome néovasculaire. |
PMID | 20579473
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Female
- Glaucoma, Neovascular
(drug therapy)
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Prospective Studies
|